Actively Recruiting
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Led by M.D. Anderson Cancer Center · Updated on 2026-04-21
200
Participants Needed
1
Research Sites
645 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
CONDITIONS
Official Title
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with monoclonal gammopathy of unknown significance (MGUS) with serum monoclonal protein less than 3 g/dL or urinary monoclonal protein less than 500 mg per 24 hours and clonal bone marrow plasma cells less than 10%
- No signs or symptoms of myeloma or amyloidosis for MGUS patients
- Patients with smoldering multiple myeloma (SMM) with serum monoclonal protein 3 g/dL or higher or urinary monoclonal protein 500 mg or higher per 24 hours and/or clonal bone marrow plasma cells between 10% and 60%
- No signs or symptoms of myeloma or amyloidosis for SMM patients
You will not qualify if you...
- Evidence of myeloma defining events or biomarkers of malignancy such as hypercalcemia, renal insufficiency, anemia, bone lesions, high clonal bone marrow plasma cell percentage, abnormal serum free light chain ratio, or multiple focal MRI lesions
- Prior or current systemic treatment for asymptomatic monoclonal gammopathies except bisphosphonates
- Radiotherapy is not permitted
- Plasma cell leukemia
- Uncontrolled illness including active infection or psychiatric/social conditions that would affect study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
M
Mei Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here